Three Markers Hiding on Every CMP That Most Practitioners Scroll Right Past

BUN, Uric Acid, and Bilirubin — The Depletion Story Nobody's Reading

Every practitioner running labs has these three markers on every comprehensive metabolic panel. Most glance at them, see they're within the reference range, and move on. But these markers carry physiological information that most training programs never teach you to extract — and when all three run low together, they reveal a depletion and detoxification pattern that connects symptoms most practitioners are chasing in circles.

Meet the Client

She's 30, chronically bloated, deals with recurring vaginal yeast infections, and has a white coating on her tongue most mornings. She's sensitive to perfumes, cleaning products, and alcohol — even one glass of wine gives her a headache within twenty minutes. She's tried multiple rounds of antifungals and probiotics. Things improve temporarily, then relapse. She has a history of long-term antibiotic use in her teens for acne. She eats primarily plant-based, low protein by anyone's measure.

Her previous practitioner ran a comprehensive panel and told her everything looked fine. You pull up her labs and look at the three markers nobody taught her practitioner to read:

Everything within conventional range. Nothing flagged. But functionally, all three target markers are running low — and the supporting markers confirm this isn't random. Low creatinine alongside low BUN reinforces the protein picture. GGT at 28 is a value many functional programs still teach as acceptable — but it's well above the female optimal of 10–20 and signals oxidative stress. Globulin at 3.4 confirms chronic immune activation. These markers are connected by a single physiological thread, and it ties directly to the symptoms she's been chasing for years.

Low BUN: The Protein Deficit Nobody's Addressing

Most practitioners understand that high BUN can signal dehydration or kidney stress. Fewer know what low BUN tells you — and it's one of the most reliable indicators of inadequate protein intake on any standard panel.

BUN below 12 mg/dL, especially alongside low creatinine, consistently correlates with insufficient protein substrate for the body's demands. For someone eating primarily plant-based with minimal animal protein, this pattern is common — and it has consequences that extend far beyond muscle maintenance.

Here's where it gets clinically important: protein insufficiency directly compromises Phase II detoxification capacity. Several of the Phase II conjugation pathways are directly amino acid-dependent — glutathione conjugation, amino acid conjugation (bile salt formation), and sulfation all require amino acid substrate to function. When protein intake is chronically low, the body doesn't have the raw materials to run these pathways at capacity.¹

For a client with a high detoxification burden — as candida overgrowth creates — low protein intake means the system that's supposed to be clearing the toxic load doesn't have the substrate it needs to function. The antifungal-probiotic cycle keeps failing because nobody's addressing the detoxification bottleneck underneath.

Low Uric Acid: The Molybdenum Depletion Signal

This is the marker where the physiology gets interesting — and where almost nobody is looking.

Most practitioners only pay attention to uric acid when it's high (gout, metabolic syndrome, fructose excess). Low uric acid gets overlooked entirely because it doesn't have a dramatic clinical presentation. But uric acid is the end product of purine metabolism, and the enzyme that produces it — xanthine oxidase — is molybdenum-dependent. When uric acid runs below the female optimal of 3.0 mg/dL, one of the most common explanations is functional molybdenum depletion.²

Here's why that matters for this client: Candida produces acetaldehyde as a primary metabolic byproduct. Acetaldehyde is the same toxic compound your body produces when you metabolize alcohol — it's the reason hangovers feel the way they do. The enzyme responsible for detoxifying acetaldehyde — aldehyde oxidase — is also molybdenum-dependent. In chronic candida overgrowth, the continuous acetaldehyde production creates a sustained demand for molybdenum that eventually depletes the body's stores.

But the consequences don't stop at uric acid. Molybdenum is also required for sulfite oxidase — the enzyme that converts toxic sulfites to safe sulfates. This connects directly to the sulfation pathway, one of the Phase II detoxification pathways. Sulfation is a primary elimination route for estrogens, catecholamines, and many environmental toxins. When molybdenum is depleted, sulfation capacity drops — and the downstream consequences include chemical sensitivities (exactly what this client describes with perfumes and cleaning products), impaired estrogen clearance, and the accumulation of sulfites that can cause headaches, flushing, and neurological symptoms.

Her wine headache within twenty minutes? That's not a sulfite "allergy." That's a sulfite processing deficit — her sulfite oxidase can't keep up because the molybdenum it requires is being consumed by the acetaldehyde detoxification demands of her candida overgrowth.

Want to learn how to read the full kidney and liver panels as interconnected metabolic patterns? The Decoding Metabolic Health course covers kidney markers, liver assessment, blood sugar, and cardiovascular patterns — all inside a focused, self-paced course from the Decoding series.

Low Bilirubin: Fat-Soluble Antioxidant Depletion Under Toxic Load

Bilirubin is a potent lipophilic (fat-soluble) antioxidant. It complements glutathione — which handles water-soluble environments — forming a two-part antioxidant system where bilirubin protects cell membranes and lipoproteins while glutathione protects the aqueous compartments.^3,4

Low bilirubin (below 0.5 mg/dL) tells you this protective system is running on empty. The three most common drivers are zinc deficiency (biliverdin reductase, the enzyme that converts biliverdin to bilirubin, is zinc-dependent⁵), excessive antioxidant consumption from high oxidative demand, and poor Phase II capacity limiting the bilirubin conjugation and recycling process.

Now look at what's sitting next to her low bilirubin: GGT at 28. Many functional programs still teach GGT as acceptable up to 26 or even 30. But the female optimal is 10–20, and GGT is the most sensitive marker for oxidative stress and detoxification burden on the CMP.⁶ A value of 28 in a 30-year-old woman isn't "borderline" — it's telling you the liver's detoxification machinery is working harder than it should be. Low bilirubin paired with elevated GGT is a detoxification stress pattern — the body's fat-soluble antioxidant system is being consumed faster than it can be replenished.

The elevated globulin (3.4 g/dL, above the functional optimal of 2.2–3.0) adds another layer — it confirms chronic immune activation, consistent with an ongoing fungal overgrowth that the immune system is perpetually fighting.

Conversely, mildly elevated bilirubin (1.0–2.0 mg/dL) with no other liver abnormalities is often Gilbert's syndrome — a benign genetic condition affecting 3–7% of the population. Research suggests it may actually be protective due to bilirubin's antioxidant properties: individuals with Gilbert's have been shown to have reduced oxidized LDL and enhanced thiol status.⁴

The Pattern: How These Three Markers Connect

What the Intervention Looks Like

The typical approach — kill the candida first, deal with symptoms later — fails precisely because it ignores the depletion pattern. This is a case where you build the infrastructure before you increase the toxic burden of die-off.

Increase protein intake substantially to provide the amino acid substrate Phase II conjugation requires. This alone begins shifting the BUN and detoxification capacity. For a plant-based client, this means an honest conversation about protein sources — whether that's adding animal protein back in, significantly increasing plant-based protein volume, or supplementing strategically.

Replete molybdenum to restore xanthine oxidase, aldehyde oxidase, and sulfite oxidase function. This addresses the uric acid deficit, restores sulfation capacity, and directly improves the body's ability to handle acetaldehyde — the primary toxic output of the candida it hasn't been able to clear.

Assess zinc status and support repletion to restore biliverdin reductase function and bilirubin production. Support the glutathione system to take pressure off bilirubin as the sole fat-soluble antioxidant defense.

Support Phase II broadly — sulfur-rich foods, adequate hydration, and ensure Phase III elimination is functioning (regular bowel movements, adequate fiber, bile flow support) before increasing the toxic burden.

Then — and only then — introduce the antimicrobial strategy. By the time you address the candida directly, the body actually has the capacity to process and eliminate what it releases. The die-off doesn't overwhelm the system because the detoxification infrastructure is already in place.

What This Means for Your Practice

These three markers are on every CMP you'll ever see. They cost nothing extra to assess. But to read them this way — as a connected depletion pattern rather than three isolated "low normal" values — requires understanding the physiology underneath each one. BUN as a protein and Phase II substrate marker, not just a kidney number. Uric acid as a molybdenum-dependent enzymatic output, not just a gout indicator. Bilirubin as a functional antioxidant with zinc-dependent production, not just a liver flag. When you see all three running low together, especially with elevated GGT, start looking for the toxic or microbial burden driving the depletion — and build the detoxification capacity before you try to kill whatever's causing it.

Frequently Asked Questions

Why does low uric acid suggest molybdenum depletion?

Uric acid is the end product of purine metabolism, and the final enzyme in the pathway — xanthine oxidase — requires molybdenum as a cofactor. When molybdenum is functionally depleted, xanthine oxidase activity drops and uric acid production falls. This is especially significant because molybdenum also supports sulfite oxidase (sulfation pathway) and aldehyde oxidase (acetaldehyde detoxification) — so low uric acid is often the visible signal of a broader enzymatic deficit.

How does candida overgrowth deplete molybdenum?

Candida produces acetaldehyde as a primary metabolic byproduct. The enzyme aldehyde oxidase — which detoxifies acetaldehyde — is molybdenum-dependent. Chronic candida overgrowth creates sustained acetaldehyde production, which places continuous demand on aldehyde oxidase and eventually depletes molybdenum stores. This is why chemical sensitivities and "wine headaches" often accompany chronic yeast overgrowth — sulfite oxidase (also molybdenum-dependent) loses capacity, and sulfite processing becomes impaired.

Why should I build detox capacity before starting antifungals?

Antimicrobial die-off releases a surge of fungal metabolites including acetaldehyde, which must be processed through Phase II detoxification pathways. If those pathways are already substrate-starved, cofactor-depleted, and antioxidant-exhausted, the die-off overwhelms the system and the client feels worse — often leading them to abandon the protocol. Building detox infrastructure first means the body can actually process what gets released.

What does low bilirubin actually tell you?

Bilirubin below 0.5 mg/dL indicates depleted fat-soluble antioxidant capacity. Bilirubin protects cell membranes and lipoproteins from oxidative damage, complementing glutathione's role in water-soluble environments. When it's low, the most common causes are zinc deficiency (biliverdin reductase requires zinc), excessive consumption from high oxidative demand, or poor Phase II processing. Low bilirubin paired with elevated GGT is a detoxification stress pattern.

Does elevated bilirubin always mean liver disease?

No. Mildly elevated bilirubin (1.0–2.0 mg/dL) with completely normal liver enzymes is often Gilbert's syndrome — a benign genetic condition affecting 3–7% of the population. Research suggests it may actually be protective: individuals with Gilbert's have reduced oxidized LDL and enhanced antioxidant status. Don't chase mildly elevated bilirubin if the rest of the liver panel is clean.

References

Written by Michael Rutherford
Wholistic Health Academy • wholistichealthacademy.org